Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | AGER | Q15109 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17306708 | 0.85 | DDB1 (0.39) | CYP1A2CYP2D6CYP2C9CYP2C19EHMT2 | |
| SCHEMBL17345633 | 0.82 | MEN1 (0.49) | CCNT1CDK9MEN1CYP1A2POLB | |
| SCHEMBL17300778 | 0.76 | HRH3 (0.34) | CCNT1CDK9 | |
| SCHEMBL17306714 | 0.74 | MCHR1 (0.38) | CCNT1CDK9MAPK14 | |
| SCHEMBL17306717 | 0.71 | HRH3 (0.34) | CCNT1CDK9 | |
| SCHEMBL17194952 | 0.69 | HMGCR (0.36) | MEN1CYP1A2POLBCYP2D6CYP2C9 | |
| SCHEMBL17300826 | 0.66 | HRH3 (0.39) | CCNT1CDK9 | |
| SCHEMBL17308279 | 0.66 | HTT (0.46) | MEN1CYP1A2KMT2ASMN1; SMN2EHMT2 | |
| SCHEMBL13927358 | 0.66 | PDE4A (0.43) | MEN1CYP2C9CYP2C19KMT2ASMN1; SMN2 | |
| SCHEMBL17300808 | 0.66 | HRH4 (0.42) | EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | CCNT1 2654/4885CDK9 339/4885MEN1 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.